Across TCGA pan-cancer cohorts, UBL4A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated UBL4A data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in uterine carcinosarcoma (UCS), where higher UBL4A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated UBL4A expression acts as an unfavorable survival marker.
UCS and BLCA are the cancer types where UBL4A Mutation most reproducibly stratifies survival.